The power of phenotypic screening was illustrated by a 2011 paper in Nature Reviews Drug Discovery that analysed how new medicines were discovered from 1999 to 2008 1.Over the period, target-based ...

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...

"We're thrilled to partner with ONCare to create a program focused on generating impactful -omics data that will accelerate biomarker discovery for high-need patient populations," said Ed Stepanski, ...

Early stage drug discovery has still not benefited from ... as well as more complex target product profiles guided by high content phenotypic data. In addition to its work with GSK and Sanofi ...

Ovation launches a GLP-1 dataset with WGS enabling biomaker discovery to advance precision medicine in metabolic diseases.

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the ...

This dynamic field has seen tremendous change in recent years. Leaders share their perspectives on what trends we can expect ...

For modern biotherapeutics, cell line development workflows must include more than just automated liquid handling.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

By providing access to high-quality genomic data linked to rich, longitudinal phenotypic data at scale, Ovation allows life sciences researchers to advance drug discovery and development more ...